Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
octreotide depot
- Development stage
- Unknown
- Lead developer
- Pharm-Sintez
- Modality
- Peptides
- Administration
- Intramuscular
01
Overview
Octreotide depot is a long-acting, prolonged-release formulation of octreotide acetate, a synthetic cyclic octapeptide analogue of the natural hormone somatostatin. Developed by Pharm-Sintez and manufactured by Empresa DECO, it acts as a potent agonist of somatostatin receptors (SSTRs), specifically SSTR2, SSTR3, and SSTR5. By mimicking the inhibitory effects of somatostatin, it suppresses the secretion of growth hormone (GH) and various gastrointestinal and pancreatic peptides, including insulin, glucagon, gastrin, and vasoactive intestinal peptide (VIP). The depot formulation, administered via intramuscular injection, allows for sustained therapeutic levels, making it suitable for the long-term management of acromegaly and symptoms associated with functional neuroendocrine tumors (NETs) such as carcinoid syndrome, VIPomas, and gastrinomas. It is also indicated for the treatment of hormone-resistant prostate cancer and the prevention of complications following pancreatic surgery.
- Brand names
- Octreotide-depoOctreotide Depot
- Other names
- octreotide acetateoctreotide depot
02
Targets
SSTR2 (Somatostatin receptor type 2)SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)
Beyond the preview
Go deeper on octreotide depot.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on octreotide depot.